|
Sunday, October 16, 2016
gaming commision percoco cuomo job well done krd for suffolk
clinton and trump hire krd
WebCivil Supreme - Motion Detail
| Court: | Nassau Civil Supreme | |
| Index Number: | 017914/2007 | |
| Case Name: | NASSAU REGIONAL OFF-TRACK vs. KRD MEDIA, LLCA | |
| Case Type: | Contract | |
| Track: | Standard |
Motion Information:
| Motion Number | Date Filed | Filed By | Relief Sought | Submit Date | Answer Demanded | Status | Decision | Order Signed Date |
|---|---|---|---|---|---|---|---|---|
| 005 | 09/23/2016 | DEF | Cross-Motion (Other) | 10/07/2016 | Yes | Open: Before Justice: MAHON | ||
| 004 | 08/24/2016 | DEF | Turn Over File (To New Atty) | 10/07/2016 | No | Open: Before Justice: MAHON | ||
| 003 | 09/28/2015 | DEF | Leave To File Lien | 10/15/2015 | Yes | Decided: 10-DEC-15 MOTION DENIED Before Justice: MAHON | Short Form Order | 12/10/2015 |
| 002 | 04/28/2014 | PLAINT | Dismiss Complaint/Petition | 08/29/2014 | Yes | Decided: 23-SEP-14 MOTION DENIED Before Justice: COZZENS | Short Form Order | 09/23/2014 |
| 001 | 09/25/2008 | PLAINT | Compel Discovery/Disclosure | 10/15/2008 | Yes | Decided: 30-OCT-08 MOTION WITHDRAWN Before Justice: SPINOLA | Short Form Order | 10/30/2008 |
Friday, October 14, 2016
go hell
people still cannot get bcg in the us to treat their sutoimmune diseases
faustmanlab.org
Who are these clowns kidding?
faustmanlab.org
Who are these clowns kidding?
WHO: TB Kills More Than HIV and Malaria, More Effort Needed
EDITORS' RECOMMENDATIONS
My Alerts
Click the topic below to receive emails when new articles are available.
RELATED DRUGS & DISEASES
With the tuberculosis (TB) epidemic worse than previously thought, killing more people than HIV and malaria, ending it will take greater global action and investment, the World Health Organization (WHO) said in a report released today.
The End TB Strategy, adopted by all WHO member states in 2014, aims to decrease TB incidence by 80% and reduce TB deaths by 90% by 2030.
"We face an uphill battle to reach the global targets for tuberculosis," Margaret Chan, MD, WHO director general, said in a news release. "There must be a massive scale-up of efforts, or countries will continue to run behind this deadly epidemic and these ambitious goals will be missed."
Bold Commitment Needed
The WHO Global Tuberculosis Report 2016 provides an update on the TB epidemic and progress in diagnosis, treatment, and prevention, as well as TB-specific funding and research. The report "signals the need for bold political commitment and increased funding," the WHO said.
It also warns that the TB epidemic is bigger than previously estimated, according to new surveillance and survey data from India.
In 2015, there were an estimated 10.4 million new TB cases worldwide. Six countries accounted for 60% of new cases: India, Indonesia, China, Nigeria, Pakistan, and South Africa. "Global progress depends on major advances in TB prevention and care in these countries," the report says.
From 2014 to 2015, the rate of decline in TB incidence worldwide remained at only 1.5%. This needs to accelerate to a 4% to 5% annual decline by 2020 to reach the first milestones of the End TB Strategy, the WHO notes. (The 2020 milestones of the End TB Strategy are a 35% reduction in the absolute number of TB deaths and a 20% reduction in the TB incidence rate, compared with levels in 2015, and that no TB-affected households face catastrophic costs.)
Globally, an estimated 1.8 million people died of TB in 2015, at least 3 people per minute, of whom 0.4 million were coinfected with HIV. Although the number of TB deaths fell by 22% between 2000 and 2015, TB remained 1 of the top 10 causes of death worldwide in 2015, responsible for more deaths than HIV and malaria, the WHO says.
MDR-TB a Public Health Crisis
While TB treatment prevented 49 million deaths globally between 2000 and 2015, "important diagnostic and treatment gaps persist," the report notes. Of the estimated 10.4 million new cases in 2015, only 6.1 million were detected and officially reported in 2015, leaving a gap of 4.3 million. This gap is due to underreporting of TB cases, especially in countries with large unregulated private sectors, and underdiagnosis in countries with major barriers to accessing care, the WHO says. India, Indonesia, and Nigeria accounted for almost half of the reporting gap.
Multidrug-resistant TB (MDR-TB) remains a public health crisis, the WHO says. In 2015, there were an estimated 480,000 new MDR-TB cases. India, China, and the Russian Federation carry the major burden of MDR-TB. "Eighty percent of the cases of MDR-TB in the world simply don't get detected and therefore are not treated. Roughly 200,000 people die of MDR-TB every year, and that's the reason why we call it a crisis," Mario Raviglione, MD, director of the WHO Global TB Programme, said during a press briefing.
"The world is finally waking up to the threat of antimicrobial resistance — now is the time to accelerate the MDR-TB response," he added in the news release.
Research Underfunded
Greater global investment in TB is needed, the report concludes. For TB care and prevention, investments in low- and middle-income countries fall nearly $2 billion short of the $8.3 billion needed in 2016, the report notes, and this gap will widen to $6 billion by 2020 if current levels of funding don't increase.
For TB research and development, at least $2 billion per year is needed. Yet funding between 2005 and 2014 never exceeded $0.7 billion per year. Despite some progress in the pipeline for new diagnostics, drugs, and vaccines, TB research and development remain "severely underfunded," the report says.
WHO estimates that at least an extra $1 billion per year is needed to accelerate the development of new vaccines, diagnostics, and drugs. There are currently 9 drugs for TB in advanced phases of clinical trials and 13 vaccine candidates, the report says.
"The resources deployed against TB, the leading infectious killer in the world, are falling short," said Ariel Pablos-Méndez, MD, assistant administrator for global health, of the US Agency for International Development, the leading bilateral funder of the TB response.
"Everyone has a part to play in closing the gap. As the report shows, we need universal health coverage, social protection mechanisms, and public health financing in high burden countries. The development aid community needs to step up more investments now, or we will simply not end one of the world's oldest and deadliest diseases," he added.
Thursday, October 13, 2016
Dr. Denise Faustman
Get updates on our research
Keep in touch with the Faustman Lab. Sign up for e-mail updates on the clinical trials and more.
>Sign up
Keep in touch with the Faustman Lab. Sign up for e-mail updates on the clinical trials and more.
>Sign up
>Get information on our clinical trials
For questions about the clinical trial, please e-mail us directly.
>E-mail us
For questions about the clinical trial, please e-mail us directly.
>E-mail us
Follow us
Watch Dr. Faustman's interview about the Phase I trial
Our Phase II Trial Has Launched Read the press release
Interested in the Phase II Trial?
Please email us directly.
------------
Your donation will directly support our Phase II research.
Raised to date: $20 million
Our total need: $25.2 million.
Raised to date: $20 million
Our total need: $25.2 million.
The Faustman Lab at Massachusetts General Hospital
Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Her current research focuses on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases, including Crohn's disease, lupus, scleroderma, rheumatoid arthritis, Sjögren's syndrome, and multiple sclerosis. She is currently leading a human clinical trial program testing the efficacy of the BCG vaccine for reversal of long-term type 1 diabetes. Positive results from the Phase I study were reported in 2012.Dr. Faustman's type 1 diabetes research has earned her notable awards such as the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist” (2005), the "Women in Science Award" from the American Medical Women’s Association and Wyeth Pharmaceutical Company for her contributions to autoimmune disease research (2006), and the Goldman Philanthropic Partnerships/Partnership for Cures “George and Judith Goldman Angel Award” for research to find an effective treatment for type 1 diabetes (2011). Her previous research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness. This achievement earned her the prestigious National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award (2003) as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States.
Dr. Faustman earned her MD and PhD from Washington University School of Medicine in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital in Boston, Massachusetts.
Subscribe to:
Posts (Atom)